Federally Sponsored Research Networks
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) was established in October 2001 to conduct large multi-institutional clinical trials. The trials will address important issues in hematopoietic stem cell transplantation (HSCT), thereby furthering understanding of the best possible treatment approaches. Participating BMT CTN investigators collaborate through an organization designed to maintain continuity of operations, to facilitate effective communication and cooperation among participating transplant centers and with collaborators at the National Institutes of Health, and to offer trials participation to patients in all regions of the U.S.
Center for Innovative Trials in Children and Adults (TRIDENT) from the National Center for Advancing Translational Sciences (NCATS)
Duke University and Vanderbilt University propose to develop the Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT) to improve trial efficiencies, reduce the costs of multi-site clinical trials, optimize study quality, and in doing so, advance health in our country. Duke and Vanderbilt Universities are uniquely poised to establish the Trial Innovation Center (TIC) infrastructure. Duke will leverage the capacity, track record, and the pediatrics clinical trials program of the world’s largest Academic Research Organization, Duke Clinical Research Institute (DCRI), with Vanderbilt’s renowned biomedical informatics enterprise to meld high quality multi-center trial management with sophisticated informatics solutions supporting trial processes.
The mission of CARRA is to conduct collaborative research to prevent, treat and cure pediatric rheumatic diseases, with a vision of a world free of limitations from pediatric rheumatic diseases. CARRA members work together to capitalize on opportunities, actively develop a structure and a scientific agenda, and collaborate with potential funding sources to create a research alliance that benefits our patients.
The Children’s Oncology Group (COG), a National Cancer Institute supported clinical trials group, is the world’s largest organization devoted exclusively to childhood and adolescent cancer research. The COG unites more than 9,000 experts in childhood cancer at more than 200 leading children’s hospitals, universities, and cancer centers across North America, Australia, New Zealand, and Europe in the fight against childhood cancer.
The Cystic Fibrosis (CF) Foundation is the world's leader in the search for a cure for cystic fibrosis, and nearly every CF-specific drug available today was made possible with our financial support. We are a donor-funded, 501(c)(3) nonprofit that is fully accredited by the Better Business Bureau's (BBB) Wise Giving Alliance program. The mission of the CF Foundation is to cure CF and to provide all people with the disease the opportunity to lead full, productive lives by funding research and drug development, promoting individualized treatment, and ensuring access to high-quality, specialized care.
The scientific goal of ECHO, a research program launched by the National Institutes of Health, is to understand the effects of a broad range of early environmental influences on child health and development. ECHO uses information from existing longitudinal research projects (cohorts) that will include more than 50,000 children from diverse backgrounds across the United States. Together, these cohorts follow participants from before they are born through childhood and adolescence. ECHO also supports a 17-state clinical trials network to test prevention and treatment strategies among children from rural and medically underserved backgrounds. The ECHO Coordinating Center is housed within the Duke Clinical Research Institute (DCRI).
The DCRI and its strategic partners were awarded a grant from the U.S. Food and Drug Administration (FDA) to establish a coordinating center for a Global Pediatric Clinical Trials Network (G-PCTN). The G-PCTN supports efficient pediatric clinical trials worldwide by developing scientific and operational infrastructure, fostering collaborative networks, sharing knowledge, and engaging stakeholders.
ImproveCareNow is a collaborative community where patients, parents, clinicians, and researchers work together to improve the health and care of children and youth with Crohn’s disease and ulcerative colitis.
The mission of IMPAACT is to significantly decrease incident HIV and HIV-associated infections and to decrease mortality and morbidity due to HIV and HIV-associated infections and co-morbidities among infants, children, adolescents and pregnant/postpartum women.
The multi-center International Pediatric Fungal Network (IPFN) was created to gain a complete understanding of the scope and character of pediatric fungal infections in order to improve the care of our patients. The primary mission of the IPFN is to increase the knowledge of pediatric invasive fungal infections and discern any undescribed characteristics or outcomes unique to pediatric patients through a coordinated network of scientific investigation.
The Neonatal Research Network was established in 1986 to address the critical need for rigorous research in babies admitted to Neonatal Intensive Care Units (NICUs), so that solid evidence generated by such research can be used to improve the treatment and health outcomes of critically ill newborn babies. Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), the Network is a collaboration between NICUs from academic medical centers across the US and a coordinating center.
The North American Pediatric Aplastic Anemia Consortium (NAPAAC) is a collaborative research effort that seeks to develop better therapies for children with aplastic anemia, inherited bone marrow failure syndromes (IBMFS), and Myelodysplastic Syndrome (MDS) by combining the expertise and resources of the leading pediatric hematologists in North America.
Through the Pediatric Heart Network (PHN), the National Heart, Lung, and Blood Institute (NHLBI) funds research across a group of hospitals in the United States and Canada to accelerate the discovery of new treatments for congenital and pediatric-acquired heart disease. The PHN is the clinical cornerstone of the larger Bench to Bassinet Program, a major effort the NHLBI launched to learn more about how the heart develops and why children are born with heart problems. The goal of the PHN is to improve outcomes and quality of life for individuals with congenital and pediatric-acquired heart disease.
Research on rare disorders such as pediatric immune thrombocytopenia (ITP) can only advance with the collaboration of physicians and investigators from multiple centers. ICON is a collaborative research effort that is dedicated to improving the understanding, treatment, and quality of life of pediatric patients with ITP. Through ICON, clinicians and researchers interested in pediatric ITP work together to initiate and conduct collaborative studies and disseminate information about ITP.
The Pediatric Trials Network is an alliance of clinical research sites located around the United States that are cooperating in the design and conduct of pediatric clinical trials to improve health care for the youngest patients. The PTN, centered at Duke, is studying the formulation, dosing, efficacy, and safety of drugs, as well as the development of medical devices, used in pediatric patients.
The Undiagnosed Diseases Network (UDN) is a research study that is funded by the National Institutes of Health Common Fund. Its purpose is to bring together clinical and research experts from across the United States to solve the most challenging medical mysteries using advanced technologies. Through this study, we hope to both help individual patients and families living with the burden of undiagnosed diseases, and contribute to the understanding of how the human body works.